Glioblastoma is considered to the most common and malignant brain tumor in adults. Patients have a median survival of approximately one year from diagnosis due to poor response to therapy.
OBJECTIVE:
We applied bioinformatics approaches to predict transcription factors (TF) that are deregulated in glioblastoma in an attempt to point out molecular targets for therapy.
METHODS:
Up-regulated genes in glioblastoma selected from public microarray data were submitted to two TF association analyses. Thereafter, the expression levels of TF obtained in the overlap of analyses were assessed by RT-qPCR carried out in seven glioblastoma cell lines (T98, U251, U138, U87, U343, M059J, and M059K).
RESULTS:
E2F1 and E2F4 were highlighted in both TF analyses. However, only E2F1 was confirmed as significantly up-regulated in all glioblastoma cell linesin vitro.
CONCLUSION:
E2F1 is a potential common regulator of differentially expressed genes in glioblastoma, despite the genetic heterogeneity of tumor cells.
BaiRY, StaedtkeV, RigginsGJ: Molecular targeting of glioblastoma: Drug discovery and therapies. Trends Mol Med2011.
4.
StuppR, GanderM, LeyvrazS, NewlandsE: Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol2001; 2: 552-560.
KandothC, McLellanMD, VandinF, YeK, NiuB, LuC, XieM, ZhangQ, McMichaelJF, WyczalkowskiMA, LeisersonMD, MillerCA, WelchJS, WalterMJ, WendlMC, LeyTJ, WilsonRK, RaphaelBJ, DingL: Mutational landscape and significance across 12 major cancer types. Nature2013; 502: 333-339.
11.
OhgakiH: Genetic pathways to glioblastomas. Neuropathology2005; 25: 1-7.
12.
da SilvaGN, EvangelistaAF, MagalhaesDA, MacedoC, BufaloMC, Sakamoto-HojoET, PassosGA, SalvadoriDM: Expression of genes related to apoptosis, cell cycle and signaling pathways are independent of TP53 status in urinary bladder cancer cells. Mol Biol Rep2011; 38: 4159-4170.
13.
GodoyPRDV, MelloSS, MagalhãesDAR, DonairesFS, MontaldiAP, NicolucciP, DonadiEA, PassosGAS, Sakamoto-HojoET: Portrait of transcriptional expression profiles displayed by different glioblastoma cell lines; in Garami M (ed): Molecular Targets of CNS Tumors. Rijeka, InTech, 2011; 1, 277-300.
14.
GodoyPR, MelloSS, MagalhaesDA, DonairesFS, NicolucciP, DonadiEA, PassosGA, Sakamoto-HojoET: Ionizing radiation-induced gene expression changes in TP53 proficient and deficient glioblastoma cell lines. Mutat Res2013; 756: 46-55.
15.
OtomoT, HishiiM, AraiH, SatoK, SasaiK: Microarray analysis of temporal gene responses to ionizing radiation in two glioblastoma cell lines: up-regulation of DNA repair genes. J Radiat Res (Tokyo)2004; 45: 53-60.
16.
EwisAA, ZhelevZ, BakalovaR, FukuokaS, ShinoharaY, IshikawaM, BabaY: A history of microarrays in biomedicine. Expert Rev Mol Diagn2005; 5: 315-328.
17.
CampainA, YangYH: Comparison study of microarray meta-analysis methods. BMC Bioinformatics2010; 11: 408.
18.
DopazoJ, ZandersE, DragoniI, AmphlettG, FalcianiF: Methods and approaches in the analysis of gene expression data. J Immunol Methods2001; 250: 93-112.
19.
RhodesDR, ChinnaiyanAM: Integrative analysis of the cancer transcriptome. Nat Genet2005; 37 Suppl: S31-37.
20.
ElkonR, LinhartC, SharanR, ShamirR, ShilohY: Genome-wide in silico identification of transcriptional regulators controlling the cell cycle in human cells. Genome Res2003; 13: 773-780.
21.
GodoyPRDV, MelloSS, DonairesFS, DonadiEA, PassosGAS, Sakamoto-HojoET: In silico analysis of transcription factors associated to differentially expressed genes in irradiated Glioblastoma cell lines; in Lichtor DT (ed): Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications, InTech, 2013; 1, 577-600.
22.
CarminatiPO, DonairesFS, GodoyPRDV, MontaldiAP, PassosGAS, MeadorJA, BalajeeAS, Sakamoto-HojoET: DNA-PK is a potential molecular therapeutic target for glioblastoma; Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications, InTech, 2013.
23.
SunL, HuiAM, SuQ, VortmeyerA, KotliarovY, PastorinoS, PassanitiA, MenonJ, WallingJ, BaileyR, RosenblumM, MikkelsenT, FineHA: Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell2006; 9: 287-300.
24.
BarrettT, SuzekTO, TroupDB, WilhiteSE, NgauWC, LedouxP, RudnevD, LashAE, FujibuchiW, EdgarR: NCBI GEO: mining millions of expression profiles-database and tools. Nucleic Acids Res2005; 33: D562-566.
25.
SaeedAI, SharovV, WhiteJ, LiJ, LiangW, BhagabatiN, BraistedJ, KlapaM, CurrierT, ThiagarajanM, SturnA, SnuffinM, RezantsevA, PopovD, RyltsovA, KostukovichE, BorisovskyI, LiuZ, VinsavichA, TrushV, QuackenbushJ: TM4: a free, open-source system for microarray data management and analysis. Biotechniques2003; 34: 374-378.
26.
TusherVG, TibshiraniR, ChuG: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA2001; 98: 5116-5121.
27.
Al-ShahrourF, MinguezP, VaquerizasJM, CondeL, DopazoJ: BABELOMICS: a suite of web tools for functional annotation and analysis of groups of genes in high-throughput experiments. Nucleic Acids Res2005; 33: W460-464.
28.
LopezF, TextorisJ, BergonA, DidierG, RemyE, GranjeaudS, ImbertJ, NguyenC, PuthierD: Transcriptome Browser: A powerful and flexible toolbox to explore productively the transcriptional landscape of the Gene Expression Omnibus database. PLoS One2008; 3: e4001.
LootsG, OvcharenkoI: ECRbase: database of evolutionary conserved regions, promoters, and transcription factor binding sites in vertebrate genomes. Bioinformatics2007; 23: 122-124.
31.
VandesompeleJ, De PreterK, PattynF, PoppeB, Van RoyN, De PaepeA, SpelemanF: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol2002; 3: RESEARCH0034.
UntergasserA, CutcutacheI, KoressaarT, YeJ, FairclothBC, RemmM, RozenSG: Primer 3 - new capabilities and interfaces. Nucleic Acids Res2012.
34.
PfafflMW, HorganGW, DempfleL: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res2002; 30: e36.
35.
RhodesDR, ChinnaiyanAM: Bioinformatics strategies for translating genome-wide expression analyses into clinically useful cancer markers. Ann N Y Acad Sci2004; 1020: 32-40.
36.
CooperCS, CampbellC, JhavarS: Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer. Nat Clin Pract Urol2007; 4: 677-687.
37.
StuppR, MasonWP, van den BentMJ, WellerM, FisherB, TaphoornMJ, BelangerK, BrandesAA, MarosiC, BogdahnU, CurschmannJ, JanzerRC, LudwinSK, GorliaT, AllgeierA, LacombeD, CairncrossJG, EisenhauerE, MirimanoffRO, Groups EOfRaToCBTaR, Group NCIoCCT: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med2005; 352: 987-996.
38.
AddeoR, De SantiMS, Del PreteS, CaragliaM: Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug. Cancer Chemother Pharmacol2009; 64: 863-866.
39.
AddeoR, CaragliaM, De SantiMS, MontellaL, AbbruzzeseA, ParlatoC, VincenziB, CarraturoM, FaiolaV, GenoveseM, CennamoG, Del PreteS: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J Neurooncol2011; 102: 417-424.
40.
IshiiN, MaierD, MerloA, TadaM, SawamuraY, DiserensAC, Van MeirEG: Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol1999; 9: 469-479.
41.
LeeHK, HsuAK, SajdakJ, QinJ, PavlidisP: Coexpression analysis of human genes across many microarray data sets. Genome Res2004; 14: 1085-1094.
42.
StuartJM, SegalE, KollerD, KimSK: A gene-coexpression network for global discovery of conserved genetic modules. Science2003; 302: 249-255.
43.
EisenMB, SpellmanPT, BrownPO, BotsteinD: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-14868.
44.
ChoiD, SharmaSM, PasadhikaS, KangZ, HarringtonCA, SmithJR, PlanckSR, RosenbaumJT: Application of Biostatistics and Bioinformatics Tools to Identify Putative Transcription Factor-Gene Regulatory Network of Ankylosing Spondylitis and Sarcoidosis. Commun Stat Theory Methods2009; 38: 3326-3338.
45.
DimovaDK, DysonNJ: The E2F transcriptional network: old acquaintances with new faces. Oncogene2005; 24: 2810-2826.
46.
van den HeuvelS, DysonNJ: Conserved functions of the pRB and E2F families. Nat Rev Mol Cell Biol2008; 9: 713-724.
47.
LiuH, DiblingB, SpikeB, DirlamA, MacleodK: New roles for the RB tumor suppressor protein. Curr Opin Genet Dev2004; 14: 55-64.
48.
GiacintiC, GiordanoA: RB and cell cycle progression. Oncogene2006; 25: 5220-5227.
49.
LiA, WallingJ, KotliarovY, CenterA, SteedME, AhnSJ, RosenblumM, MikkelsenT, ZenklusenJC, FineHA: Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res2008; 6: 21-30.
50.
GygiSP, RochonY, FranzaBR, AebersoldR: Correlation between protein and mRNA abundance in yeast. Mol Cell Biol1999; 19: 1720-1730.
51.
ChenG, GharibTG, HuangCC, TaylorJM, MisekDE, KardiaSL, GiordanoTJ, IannettoniMD, OrringerMB, HanashSM, BeerDG: Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics2002; 1: 304-313.
52.
LinB, WhiteJT, LuW, XieT, UtlegAG, YanX, YiEC, ShannonP, KhrebtukovaI, LangePH, GoodlettDR, ZhouD, VasicekTJ, HoodL: Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease. Cancer Res2005; 65: 3081-3091.
53.
VogelTW, ZhuangZ, LiJ, OkamotoH, FurutaM, LeeYS, ZengW, OldfieldEH, VortmeyerAO, WeilRJ: Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme. Clin Cancer Res2005; 11: 3624-3632.
54.
DeGregoriJ, JohnsonDG: Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis. Curr Mol Med2006; 6: 739-748.
55.
RakhaEA, PinderSE, PaishEC, RobertsonJF, EllisIO: Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis. J Pathol2004; 203: 754-761.
56.
ParikhN, HilsenbeckS, CreightonCJ, DayaramT, ShuckR, ShinbrotE, XiL, GibbsRA, WheelerDA, DonehowerLA: Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. J Pathol2014; 232: 522-533.
57.
JohnsonDG, DegregoriJ: Putting the Oncogenic and Tumor Suppressive Activities of E2F into Context. Curr Mol Med2006; 6: 731-738.
58.
WalterKA, HossainMA, LuddyC, GoelN, ReznikTE, LaterraJ: Scatter factor/hepatocyte growth factor stimulation of glioblastoma cell cycle progression through G(1) is c-Myc dependent and independent of p27 suppression, Cdk2 activation, or E2F1-dependent transcription. Mol Cell Biol2002; 22: 2703-2715.
59.
LinCJ, ChangYA, LinYL, LiuSH, ChangCK, ChenRM: Preclinical effects of honokiol on treating glioblastoma multiforme via G1 phase arrest and cell apoptosis. Phytomedicine2016; 23: 517-527.
60.
KaelinWG: E2F1 as a target: Promoter-driven suicide and small molecule modulators. Cancer Biol Ther2003; 2: S48-54.
61.
BandaraLR, GirlingR, La ThangueNB: Apoptosis induced in mammalian cells by small peptides that functionally antagonize the Rb-regulated E2F transcription factor. Nat Biotechnol1997; 15: 896-901.
MendozaN, FongS, MarstersJ, KoeppenH, SchwallR, WickramasingheD: Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth. Cancer Res2003; 63: 1020-1024.
